Nature Communications (Apr 2022)

USP25 promotes pathological HIF-1-driven metabolic reprogramming and is a potential therapeutic target in pancreatic cancer

  • Jessica K. Nelson,
  • May Zaw Thin,
  • Theodore Evan,
  • Steven Howell,
  • Mary Wu,
  • Bruna Almeida,
  • Nathalie Legrave,
  • Duco S. Koenis,
  • Gabriela Koifman,
  • Yoichiro Sugimoto,
  • Miriam Llorian Sopena,
  • James MacRae,
  • Emma Nye,
  • Michael Howell,
  • Ambrosius P. Snijders,
  • Andreas Prachalias,
  • Yoh Zen,
  • Debashis Sarker,
  • Axel Behrens

DOI
https://doi.org/10.1038/s41467-022-29684-9
Journal volume & issue
Vol. 13, no. 1
pp. 1 – 18

Abstract

Read online

The biological roles of deubiquitinating enzymes (DUBs) in pancreatic ductal adenocarcinoma (PDAC) are not fully explored. Here the authors perform activity based proteomics with a loss of function genetic screen and identify that USP25 promotes PDAC growth and survival through HIF-1 protein stability and transcriptional activity.